Es el momento más que perfecto para que conozcas todos los detalles del final de la película 'Fabricante de lágrimas' que ...

13/08 Rigel Pharmaceuticals annonce la disponibilité de VEPPANU (vepdegestrant) pour les patientes atteintes d'un cancer du sein avancé ou métastatique ER+/HER2- présentant une mutation ESR1 CI 13/08 ...

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and ...

Rigel Pharmaceuticals is upgraded to a speculative Buy as profitability and product momentum improve. Gavreto acquisition has materially boosted revenue and is valued at ~$245M NPV, about half RIGL's ...

Rigel Pharmaceuticals’ RIGL first product, Tavalisse (fostamatinib disodium hexahydrate), has been driving the majority of the company’s revenues. The drug remains a key top-line driver for the ...

Detailed price information for Rigel Pharmaceuticals (RIGL-Q) from The Globe and Mail including charting and trades.

Rigel's Q2 beat big ($78.7M revenue, $0.88 EPS), driven by TAVALISSE, but GAVRETO's year-over-year decline is concerning. Guidance raise came from contract revenue, not accelerating core product sales ...

Rigel's stock jumps on start of Phase 2 trial for investigational COVID-19 treatment Shares of Rigel Pharmaceuticals Inc. were up 10.4% in premarket trading on Thursday after the company said it had ...

VEPPANU is the first and only FDA-approved PROTAC and has the potential to become an important new treatment option for adult patients with 2L+ ER+/HER2-, ESR1-mutated mBC "The commercial launch of ...

SOUTH SAN FRANCISCO, Calif., July 28, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its second quarter 2026 financial results after market close ...